General
Preferred name
methotrimeprazine
Synonyms
levomepromazine ()
Methotrimeprazine maleat salt ()
Levomepromazine (maleate) ()
Methotrimeprazine (maleate) ()
LEVOMEPROMAZINE HYDROCHLORIDE ()
LEVOMEPROMAZINE MALEATE ()
Sofmin ()
Levomepromazinum ()
Neurocil ()
Nozinan ()
Tisercin ()
Levomepromazine hydrogen maleate ()
Levinan ()
Hirnamin ()
Neuractil ()
Milezin ()
Minozinan ()
Veractil ()
XP03 ()
RP 7044 ()
XP-03 ()
CL 36467 ()
CL-36467 ()
SK&F-5116 ()
Levoprome ()
RP-7044 ()
NSC-226516 ()
N05AA02 ()
SK&F 5116 ()
Levomepromazina ()
Nirvan ()
Neozine ()
CL 39743 ()
CL-39743 ()
Levomepromazine hcl ()
Methotrimeprazine hydrochloride ()
P&D ID
PD009513
CAS
7104-38-3
60-99-1
1236-99-3
Tags
available
drug candidate
drug
Approved by
FDA
Drug indication
Psychotic disorder
Bipolar disorder
Psychosis
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
First approval
1982
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Levomepromazine maleate (Methotrimeprazine maleate) is an N-substituted phenylthiazine antipsychotic sedative that blocks multiple receptors. Levomepromazine maleate is a potent inhibitor of CYP2D6 and is useful in the study of schizophreni[1][2].
DESCRIPTION Marketed formulations contain either levomepromazine hydrochloride or levomepromazine maleate. (GtoPdb)
DESCRIPTION Levomepromazine (Methotrimeprazine) is an orally active antipsychotic compound and Ca2+ release inducer. Levomepromazine inhibits SERCA pump and induces an increase in cytoplasmic Ca2+ levels. Levomepromazine has antagonistic effects on a variety of neurotransmitter receptors, including dopamine, cholinergic, serotonin, and histamine receptors. Levomepromazine can induce adaptive ER stress and autophagy. In addition, Levomepromazine has antiviral, anti-inflammatory, neuroprotective and analgesic, sedative and anti-injurious activities. Levomepromazine can be used in the study psychiatric disorders and relieving nausea and vomiting[1][2][3][4].
PRICE 230
DESCRIPTION Levomepromazine (Methotrimeprazine) is an orally active aliphatic phenothiazine antipsychotic compound and a Ca2+ release inducer, exhibiting antiviral, anti-inflammatory, neuroprotective, analgesic, and anti-nociceptive activities. Levomepromazine inhibits dopaminergic, cholinergic, serotoninergic, and histaminergic receptors, and is used for research in neurodegenerative diseases. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
15
ChEMBL Approved Drugs
CHEMBL1764
ChEMBL Drugs
CHEMBL1725730
CHEMBL1764
CHEMBL2104973
Drug Repurposing Hub
DrugBank
DB01403
DrugBank Approved Drugs
DB01403
DrugCentral
1752
DrugCentral Approved Drugs
1752
DrugMAP
DMIKFEL
DrugMAP Approved Drugs
DMIKFEL
Guide to Pharmacology
7603
MedChem Express Bioactive Compound Library
HY-W344044
HY-B1693
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
T15743
Withdrawn 2.0
1360
External IDs
61
Properties
(calculated by RDKit )
Molecular Weight
328.16
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
4.5
TPSA
15.71
Fraction CSP3
0.37
Chiral centers
1.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
GPCR/G protein
Immunology/Inflammation
Membrane Transporter/Ion Channel
Metabolism
Microbiology/virology
Neuroscience
Anti-infection
Neuronal Signaling
Metabolic Enzyme/Protease
Indication
psychosis, schizophrenia, bipolar disorder, nausea, insomnia
Disease Area
neurology/psychiatry, gastroenterology
Target
ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, DRD5, HRH1, HTR2A, HTR2C
5-HT Receptor
Calcium Channel
Dopamine Receptor
Enterovirus
Histamine Receptor
Cytochrome P450
Fungal
Histamine
Calcium Channel Receptor
MOA
Dopamine Receptor antagonist
ATC
N05AA02
Source data